Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Open-Label Non-Interventional, Non-Controlled Multi Observational and Pharmaco-Economic Phase IV Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar as Well as Effectiveness, Safety and Direct Medical Costs of Nexavar Treatment Under Daily-Life Treatment Conditions.

Next Previous
Search
Trial Profile

Prospective Open-Label Non-Interventional, Non-Controlled Multi Observational and Pharmaco-Economic Phase IV Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar as Well as Effectiveness, Safety and Direct Medical Costs of Nexavar Treatment Under Daily-Life Treatment Conditions.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bayer

    • Most Recent Events

    • 15 Jun 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 15 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Apr 2010 Planned end date changed from 1 Apr 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top